UK and US agree zero-tariff deal on pharmaceuticals
The Trump administration said that in return, U.K. drugs firms committed to invest more in the U.S. and create more jobs.
Pharmaceutical
-
Q&A with Cory Lewis, whose emphasis on collaboration has driven INCOG’s rapid growth
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
IBJ Podcast: The risks tariffs pose to Indiana’s manufacturing-heavy economy
President Trump wasted little time turning to economic policy once his second term began, imposing or threatening to impose a barrage of tariffs on many of Indiana’s trading partners.
Read More
Articles
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Trump administration says lower prices for 15 Medicare drugs will save taxpayers billions of dollars
The latest negotiated prices apply to some of the prescription medications on which Medicare spends the most money.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Judge formally approves Purdue Pharma opioid settlement, with Sacklers paying up to $7B
Thousands of victims of the opioid epidemic could be paid thousands of dollars each, with a portion of the money distributed next year to some people who had OxyContin prescriptions and their survivors.
The surprising new use for GLP-1s: Alcohol and drug addiction
As GLP-1 drugs for weight loss and diabetes drugs such as Zepbound and Mounjaro generate billions in sales, researchers at Eli Lilly and Co. and other pharma companies are exploring their potential for other purposes.
UPDATE: Eli Lilly stock reaches new high, tops $1,000-per-share mark
Lilly’s shares have taken off in the wake of several significant deals and after it received fast-track regulatory review for highly anticipated weight-loss pill orforglipron.
Trump unveils deal with Lilly, Novo to expand coverage, lower costs on obesity drugs
Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters.
UPDATE: White House nears deal with Lilly, Novo to slash obesity drug prices for Medicare
The deal is seen as one of the most significant in the administration’s current drug-pricing push, given the potential effect on public health and spending on health care.
Eli Lilly to build $3B manufacturing site in Netherlands
The facility is expected to produce oral medications, including Lilly’s highly anticipated GLP-1 pill for weight loss, orforglipron.
IU-Lilly study to explore drugs’ impact on job productivity
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
Lilly earnings soar on growth of Mounjaro, Zepbound
With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion.
Lilly expands Zepbound direct-to-patient access through Walmart partnership
Through its LillyDirect pharmacy, Eli Lilly plans to offer steep discounts on single-dose vials of Zepbound by partnering with the nation’s largest retail chain.
Lilly plans $1.2B expansion in Puerto Rico, adding 100 manufacturing jobs
Indianapolis-based Eli Lilly and Co. said the improved facility in Carolina, Puerto Rico, will make orforglipron, Lilly’s highly anticipated weight loss pill.
Lilly partners with Indian company to sell blockbuster weight-loss drug under new name
Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.
Novo, Lilly shares fall as Trump touts ‘much lower’ Ozempic price
Mehmet Oz, head of the Centers for Medicare and Medicaid Services, said talks over the price of weight-loss drugs are still ongoing.
Lilly to spend more than $1B to expand operations in India
Indianapolis-based Eli Lilly and Co. said the investment will strengthen its manufacturing and supply capabilities to support its growing portfolio of drugs.
Drugmakers buoyed as Trump deal eases worst fears on pricing
Shares in Indianapolis-based Eli Lilly and Co. were on the rise Wednesday after President Trump suggested the company would be next up to cut a deal over drug pricing.
Cardinal Health to build automated distribution center in Indianapolis
Employees at the facility will work alongside a robotic storage and retrieval system that can provide real-time information regarding inventory, order fulfillment and material flow.
Trump to announce drug-pricing deal with Pfizer, new ‘TrumpRx’ website
The announcements are part of an effort to secure “Most Favored Nation” pricing deals with pharmaceutical manufacturers, an effort to link U.S. drug prices to the lowest cost of drugs paid by the wealthiest countries.